Combination treatment for relapsed or refractory peripheral T cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of two drugs—a chemotherapy called mitoxantrone hydrochloride liposome and an immunotherapy called enlonstobart—for people with peripheral T cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have a confirmed diagnosis of peripheral T cell lymphoma (a type of lymphoma) that has returned or not responded to at least 4 cycles of standard chemotherapy.
- You are able to perform daily activities with some help (ECOG score 0-2).
- You have at least one measurable or evaluable tumor lesion as seen on imaging (like CT or PET scans).
- Your blood counts, liver, kidney, and thyroid function must be within acceptable ranges.
- You must not have had certain prior treatments, like high doses of anthracyclines or mitoxantrone, within a certain time frame.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (zeprumetostat, azacitidine, and a liposomal form of mitoxantrone) for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a new combination of two drugs, SHR2554 and liposomal mitoxantrone, as the first treatment for peripheral T-cell lymphoma (PTCL), a rare type of blood cancer. The goal is to see if this combination is safe and effective.
This study tests a new combination therapy with a drug called tazemetostat for people with peripheral T-cell lymphoma that has relapsed (come back) or is refractory (did not respond to previous treatment). The goal is to see if this combination can help control the lymphoma.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This trial tests a combination of three drugs (mitoxantrone liposome, cytarabine, and venetoclax) for people with AML that has returned or not responded to treatment. The goal is to see if this combination can help control the leukemia.
This trial tests a new combination of drugs (mitoxantrone liposome plus others) for people with AML that has returned or hasn't responded to treatment. The goal is to see if the combination is safe and effective.
Hear when a new Relapsed or Refractory Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.